AMYL-00z

AMYL-00z is a monoclonal antibody in preclinical development by Amyl Therapeutics for the treatment of systemic amyloidosis, specifically AL amyloidosis and transthyretin (aTTR) amyloidosis. The drug is built on the company's proprietary Pan-Amyloid Immunotherapy (PAI) platform, which generates antibodies that recognize the cross-β sheet conformation common to all amyloid aggregates regardless of the precursor protein. By targeting this specific structural motif, AMYL-00z binds to misfolded immunoglobulin light chains and transthyretin aggregates to promote their clearance from affected tissues. The candidate has been engineered to optimize safety, specifically aiming to avoid risks such as amyloid-related imaging abnormalities (ARIA), and is tailored for systemic therapeutic applications.